Latest news for Novartis (OTC:NVSEF) Stock

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

News

Intraday Update

Markets

Movers

Trading Ideas

AAXN

ACCO

ACEL

ADNT

ADUS

AFGC

AGRX

AIQUY

AIXXF

AKAM

AKBA

ALKEF

ALLE

ALSWF

ALVVF

AMAT

AMBA

AMED

AMOV

AMRC

AMVGF

APAM

APEMY

APTO

ARCC

ARES

ARNC

ASAGF

ASHTF

ASML

ASTE

ATRC

ATVI

AVMXF

AVRO

BAESY

BCLI

BEVFF

BFAM

BFST

BILI

BILL

BLOK TECHNOLOGIES INC by Blok Technologies Inc.

BLPFF

BMRMF

BOWFF

BSEFY

BSRTF

BTCY

BTDPY

BWXT

BXMT

CALX

CCMP

CCYC

CHDN

CIGI

CMFO

CMWAY

COFS

Stocks That Hit 52-Week Highs On Wednesday

ABLZF

ACDSF

ACLS

ACRE

ADBE

ADCOF

ADSK

ADYEY

AGNC

ALEC

ALFVY

AMZN

ANSS

APPF

ASPU

BCPC

BESIY

BKOR

BROG

BTAI

CBSH

CCLAY

CCOEY

CCXI

CDAY

CERN

CGEN

CIFAF

CLPBF

CLPBY

CNSWF

CPRT

CSGP

CTAS

DDOG

DOCU

DOOO

DPDW

DSGX

ENAKF

ENBP

ENPH

EPAM

Eaton Vance Tax-Advantaged Global Dividend

AAON

ADYYF

ALPMY

APLT

ATBPF

CHTR

CLHRF

CNNE

CPSH

CRMT

CVCO

CWST

DECK

DXCM

EDPFY

ELVT

EPRT

FATE

Flaherty Crumrine/Claymore Preferred Securities

FJTSY

FLEX

FORTY

FTMNF

GLDLF

GLPI

GLVMF

HNNMY

INVH

ITCC

ITMR

KDDIY

LBRDA

LBRDK

LJUIF

LLIT

MCBI

MCRI

MDLZ

MGEE

MGRUF

Blackrock Muniholdings New York Quality Fund

MKTAY

MLKKF

MSCI

Blackrock Muniholdings California Quality Fund

NDAQ

Nuveen Insured Tax-Free Advantage Municipal Fund

Nuveenn Intermediate Duration Quality Municipal Term Fund Common Shares of Beneficial Interest

Nuveen Georgia Dividend Advantage Municipal Funds 2

Nuveen Insured California Tax-Free Advantage Municipal Fund

Nuveen Municipal High Income Opportunity Fund

Stocks That Hit 52-Week Highs On Friday

Novartis AG

Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue

Aristotle Capital International Equity Q2 2024 Commentary

Roche Holding AG: A More Optimal Investment Vis-A-Vis NVS

Novartis beats top-line and bottom-line estimates; raises FY24 core operating income outlook

Earnings summary: Novartis beats Q2 earnings estimates; raises FY2024 bottom-line guidance

Novartis AG (NVS) Q2 2024 Earnings Call Transcript

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Novartis

News

Latest news for Novartis (OTC:NVSEF) Stock

Wednesday, February 12, 2020

Wednesday, February 05, 2020

Friday, January 31, 2020

Friday, January 17, 2020

Thursday, January 09, 2020

Tuesday, July 23, 2019